Nanjing Heron Pharmaceutical Co.,Ltd.

Primary objective: To evaluate the efficacy of HR1405-01 injection in treating moderate to severe pain after orthopedic surgery. Secondary objectives: To evaluate the safety of HR1405-01 injection in treating moderate to severe pain after orthopedic surgery. To evaluate the pharmacokinetic characteristics of HR1405-01 injection in treating moderate to severe pain after orthopedic surgery.

Primary Study Objectives: 1. To evaluate the pharmacokinetic characteristics of HR1405-01 injection in participants with mild to moderate hepatic impairment and normal liver function. Secondary Study Objectives: 1. To evaluate the safety of HR1405-01 injection in participants with mild to moderate hepatic impairment and normal liver function. 2. To evaluate the pharmacokinetic characteristics of the metabolite M8 of HR1405-01 injection in participants with mild to moderate hepatic impairment and normal liver function.

Primary Study Objectives: 1. To evaluate the pharmacokinetic characteristics of HR1405-01 injection in participants with mild, moderate, and severe renal impairment and those with normal renal function. Secondary Study Objectives: 1. To evaluate the safety of HR1405-01 injection in participants with mild, moderate, and severe renal impairment and those with normal renal function; 2. To evaluate the pharmacokinetic characteristics of the metabolite M8 of HR1405-01 injection in participants with mild, moderate, and severe renal impairment and those with normal renal function.